ArticleFrontiers in oncology2023

Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer.

Lindsey Gallagher et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.